Gemini PharmChem Mannheim GmbH activities are under full compliance with the worldwide valid GMP regulations. Gemini PharmChem develops a manufacturing process for New Chemical Entities (NCE) and/or supply the active pharmaceutical ingredients for all phases of a drug's life cycle, beginning with material for the first clinical studies up to the commercial supply.

Production assures the highest, consistent quality of their APIs to enable customers to run an effective process for the production of the finished drug forms.

Each year, approximately 300 kg of Active Pharmaceutical Ingredients, from 100 grams to 150 kilograms, leave their company and are delivered to customers in 21 countries on 5 continents. Gemini's team has significant experience in route development, optimization, scale-up pilot, and commercial scale chemistry for GMP and non-GMP productions.

Nuvalore GmbH mission is to create a perfect link between science and quality to ensure world-class laboratory services for companies in the pharmaceutical and life science industries. Their core expertise lies particularly in the areas of analytical quality by design (AQbD), method development and validation, method transfer, and routine analytics for quality control. Nuvalore`s team consists of scientists with many years of experience in the industry and deep knowledge of regulatory requirements. That's why they focus on advanced methods and technologies to meet highest quality standards.

The selection of suitable analytical methods for product characterization ensures a better understanding of both product and process. Nuvalore helps their customers to deepen this understanding and bring a safe product to the market.

Panasome GmbH - A new path to immunity. Panosome uses its novel, proprietary technology platform to generate antibodies to challenging disease targets. The VAST technology platform unlocks antibodies to small molecules, peptides, and proteins and the high on-target specificity of Panosome's antibodies limits side effects.

They focus their development pipeline on cancer indications with a very high medical need. For this, Panasome generates monoclonal antibodies against tumor-specific carbohydrates (such as MUC1) to target pancreatic cancer that expresses aberrantly glycosylated MUC-1 and a T cell receptor-like antibodies to target intracellular cancer antigens displayed on antigenic presenting cells.

Panasome applies this concept to specifically target a mutation connected to the rare disease midline glioma, an aggressive brain cancer that predominantly affects children.